



## Authors' Reply to Colak et al.: "Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing"

Danielle Dixon<sup>1</sup> · Michael Edmonds<sup>1</sup>

Accepted: 13 January 2022 / Published online: 17 February 2022  
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Dear Editor,

We are sorry not to have referred in our review article [1] to the paper entitled "Comparison of the effects of cilostazol and aspirin on wound healing in patients with diabetic foot ulcer and peripheral artery disease" by Colak B, Orhan A, Ece I, Yormaz S, Yilmaz H, Sahin M [2]. In our section on Cilostazol, we stated "However, no comparison studies have been performed to identify the efficacy of cilostazol in diabetic ulcer healing to date."

The explanation for the omission of the paper by Dr Bayram Colak et al is simply related to dates. Their paper was published in January 2020. As part of the preparation of our paper, our literature search was completed in December 2019. We submitted the first draft of our review in March 2020 with a subsequent redraft submitted in July 2020. The review was accepted for publication in September 2020 and published on December 31st 2020. In retrospect, we should have indicated in our review paper, the dates when our search of the literature was carried out.

Dr Bayram Colak and colleagues reported that wound healing was faster in the cilostazol group, compared to the aspirin group [2]. The paper is of interest and we are grateful to them for bringing it to the readers' attention in their letter [3].

---

This comment refers to the article available online at <https://doi.org/10.1007/s40265-020-01415-8>.

---

This reply refers to the comment available online at <https://doi.org/10.1007/s40265-022-01673-8>.

---

✉ Danielle Dixon  
danielle.dixon@nhs.net

<sup>1</sup> Diabetic Foot Clinic, King's College Hospital, Denmark Hill, London SE5 9RS, UK

### Declarations

**Funding** Not applicable.

**Conflict of interest** Danielle Dixon—no conflicts of interest, nothing to declare. Michael Edmonds—advisory Board, Uργο Medical, Bayer AG, Biomonde, Molnlycke.

**Ethics approval** Not applicable.

**Consent to participate** Not applicable.

**Consent for publication** Not applicable.

**Availability of data and material** Not applicable.

**Code availability** Not applicable.

**Author contributions** DD and ME contributed equally to this reply.

### References

1. Dixon D, Edmonds M. Managing diabetic foot ulcers: pharmacotherapy for wound healing. *Drugs*. 2021;81(1):29–56.
2. Colak B, Orhan A, Ece I, et al. Comparison of the effects of cilostazol and aspirin on wound healing in patients with diabetic foot ulcer and peripheral artery disease. *Ann Ital Chir*. 2020;91(2):225–32.
3. Colak B, Orhan A, Ece I, et al. Comment on: "Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing". *Drugs*. 2022. <https://doi.org/10.1007/s40265-022-01673-8>.